Dendritic cell subsets in type 1 diabetes: Friend or foe?

25Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin-producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective and pathogenic effects and a newly described merocytic DC population has been shown to break tolerance in the mouse model of T1D, the non-obese diabetic (NOD) mouse. We have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of DC therapy in T1D diabetes have been initiated. In this review we will critically examine the recent published literature on the role of DC subsets in the induction and regulation of the autoimmune response in T1D.

Cite

CITATION STYLE

APA

Morel, P. A. (2013). Dendritic cell subsets in type 1 diabetes: Friend or foe? Frontiers in Immunology. https://doi.org/10.3389/fimmu.2013.00415

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free